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Abstract
The nuclear orphan receptor peroxisome proliferator-activated receptor-gamma (PPAR-c) is expressed in multiple cell types
in addition to adipocytes. Upon its activation by natural ligands such as fatty acids and eicosanoids, or by synthetic agonists
such as rosiglitazone, PPAR-c regulates adipogenesis, glucose uptake and inflammatory responses. Recent studies establish
a novel role for PPAR-c signaling as an endogenous mechanism for regulating transforming growth factor-ß (TGF-ß)-
dependent fibrogenesis. Here, we sought to characterize PPAR-c function in the prototypic fibrosing disorder systemic
sclerosis (SSc), and delineate the factors governing PPAR-c expression. We report that PPAR-c levels were markedly
diminished in skin and lung biopsies from patients with SSc, and in fibroblasts explanted from the lesional skin. In normal
fibroblasts, treatment with TGF-ß resulted in a time- and dose-dependent down-regulation of PPAR-c expression. Inhibition
occurred at the transcriptional level and was mediated via canonical Smad signal transduction. Genome-wide expression
profiling of SSc skin biopsies revealed a marked attenuation of PPAR-c levels and transcriptional activity in a subset of
patients with diffuse cutaneous SSc, which was correlated with the presence of a ‘‘TGF-ß responsive gene signature’’ in
these biopsies. Together, these results demonstrate that the expression and function of PPAR-c are impaired in SSc, and
reveal the existence of a reciprocal inhibitory cross-talk between TGF-ß activation and PPAR-c signaling in the context of
fibrogenesis. In light of the potent anti-fibrotic effects attributed to PPAR-c, these observations lead us to propose that
excessive TGF-ß activity in SSc accounts for impaired PPAR-c function, which in turn contributes to unchecked fibroblast
activation and progressive fibrosis.
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Introduction
Systemic sclerosis (SSc) is a complex autoimmune disease of
unknown etiology associated with early and transient inflamma-
tion and vascular injury, followed by progressive fibrosis affecting
the skin and multiple internal organs [1]. Fibrosis, the distinguish-
ing pathological hallmark of SSc, is characterized by overproduc-
tion of collagen and other extracellular matrix (ECM) components
and accumulation of a-smooth muscle actin (ASMA)-positive
myofibroblasts, resulting in excessive connective tissue accumula-
tion and matrix remodeling.
Unchecked fibroblast activation in SSc is the result of a complex
series of events orchestrated by transforming growth factor-ß
(TGF-ß), a multifunctional cytokine that is produced and secreted
by most cell types, and also stored in a latent form in the
pericellular matrix [2]. TGF-ß signaling is initiated by ligand
binding to the type II TGF-ß receptor (TßRII), which leads to
activation of the type I TGF-ß receptor (TßRI). Activated TßRI
phosphorylates cytoplasmic Smad2 and Smad3, promoting the
formation of Smad heterocomplexes and their nuclear accumu-
lation. Within the nucleus, the Smad complex selectively binds to
conserved Smad binding element (SBE) DNA sequences, recruits
the histone acetyltransferase p300 and other coactivators, and
activates or represses the transcription of target genes such as pro-
aI (1) collagen (COL1A1) and collagenase-1, respectively [3,4,5,6].
Peroxisome proliferator-activated receptor-gamma (PPAR-c)i s
a nuclear orphan receptor and ligand-inducible transcription
factor. Initially identified in adipocytes, PPAR-c was shown to
function as a key regulator of normal adipogenesis [7]. During the
past decade, it has become apparent that PPAR-c is widely
expressed in mammalian tissues, and regulates not only genes
involved in lipid uptake, synthesis and storage, but also glucose
metabolism, cell differentiation, survival and proliferation, and
immune and inflammatory responses [8,9]. Naturally-occurring
ligands such as 15-deoxy-D12, 14-prostaglandin J2 (15d-PGJ2) and
lysophosphatidic acid (LPA), as well as synthetic ligands such as
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3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO), directly bind
to intracellular PPAR-c and trigger conformational changes that
results in recruitment of the transcriptional coactivators steroid
receptor coactivator, retinoid X receptor-alpha and p300/CBP
[10]. Within the nucleus, the ligand-PPAR-c complex binds to
PPAR response element (PPRE) DNA sequences of target genes,
and positively or negatively regulates their transcription [11].
In addition to its well-established impact on adipogenesis and
glucose homeostasis, PPAR-c appears to have an important novel
role in the negative regulation of connective tissue biosynthesis, and
is increasingly implicated in both physiologic and pathological
matrix remodeling [12]. We have shown that natural and synthetic
PPAR-c ligands, while having little effect on basal rates of collagen
synthesis and ASMA expression, effectively blocked the stimulation
of these fibrotic responses elicited by TGF-ß [13]. The potent anti-
fibrotic effects of the PPAR-c ligands involved the disruption of
Smad-dependent intracellular signal transduction via PPAR-c-
mediated transrepression [14]. Subsequent studies using a variety
of cell types have confirmed and expanded on these findings
[15,16,17]. Moreover, treatment with synthetic PPAR-c ligands was
shown to attenuate experimentally-induced hepatic [18], cardiac
[19] and kidney [20] fibrosis, and prevent bleomycin-induced
scleroderma [21], in vivo. Additionally, the expression of PPAR-c is
markedly diminished in lesional tissues in rodent models of fibrosis
and scleroderma [21,22,23], as well as in lesional skin from patients
with cicatrical (scarring) alopecia [24]. These observations provide
compelling support for a physiological role for PPAR-c in
modulating fibroblast activation and matrix remodeling.
In light of the ability of ligand-activated PPAR-c to disrupt
intracellular TGF-ß signal transduction and prevent excessive
fibroblast activation, its levels and biological availability in a
particular cell or tissue might be one of the critical factors
governing the duration and intensity of profibrotic responses.
Indeed, we have shown that augmenting cellular PPAR-c in
normal fibroblasts by ectopic overexpression markedly enhanced
their sensitivity to PPAR-c agonists [13]. However, the mecha-
nisms that regulate the cell-type-specific abundance and activity of
PPAR-c are poorly understood. We therefore sought to investigate
the regulation of PPAR-c expression in SSc, and in explanted lung
and dermal fibroblasts. We show here that PPAR-c expression was
markedly diminished in skin and lung biopsies from patients with
diffuse cutaneous SSc, as well as in unstimulated fibroblasts
explanted from the lesional skin. Incubation of normal fibroblasts
with TGF-ß induced a time- and dose-dependent suppression of
PPAR-c gene transcription and activity. Inhibition was mediated
via the canonical Smad signal transduction pathway. These results
reveal a reciprocal functionally antagonistic relationship between
ligand-dependent PPAR-c signaling that blocks Smad-mediated
TGF-ß responses, and Smad-mediated TGF-ß signaling which is
shown here to suppress the transcription and activity of PPAR-c.
Unchecked TGF-ß signaling in lesional tissue might account for
the impaired local PPAR-c expression and function in patients
with dcSSc. Fibroblasts activated via autocrine or paracrine TGF-
ß and consequently defective in PPAR-c function might be unable
to properly modulate TGF-ß signaling, resulting in unchecked
fibrogenic stimulation that could contribute to persistence and
progression of fibrosis in SSc.
Results
PPAR-c expression is reduced in systemic sclerosis
In light of the potent anti-fibrotic activities associated with the
PPAR-c pathway, and the demonstration of diminished PPAR-c
expression in various models of fibrosis, we sought to explore the
possibility that deregulated fibrogenesis in SSc was accompanied by
tissue-specific alterations in PPAR-c. To examine genome-wide
changes in RNA expression, a previously described skin biopsy-
derived microarray dataset was interrogated [25]. Analysis of the
data showed that levels of PPAR-c mRNA in the skin were reduced
in biopsies from dcSSc patients compared to healthy controls
(Fig. 1A). In contrast, plasminogen activator inhibitor-1 (PAI-1), a
TGF-ß-regulated gene that is associated withfibrosis andimplicated
in its pathogenesis, showed increased expression in SSc biopsies
[26,27]. Intriguingly, expression levels of PAI-1 and PPAR-c
mRNA were inversely correlated in these samples (Fig. 1A).
To evaluate the levels of PPAR protein in the skin, biopsies from
three patients with SSc and three healthy controls were examined
by immunohistochemistry. Low levels of PPAR-c could be
detected in the normal dermis, consistent with prior reports
[28]. Detectable PPAR-c in these skin biopsies was localized
mostly to the cells of the epidermis, with scattered dermal cells
showing positive immunostaining (Fig. 1B). Lesional skin biopsies
from patients with dcSSc consistently showed markedly reduced
PPAR-c immunostaining in the epidermis, and a complete
absence of PPAR-c in the dermis.
Because pulmonary fibrosis commonly complicates SSc, we
next examined the expression of PPAR-c in the lungs. For this
purpose, lung biopsies from five SSc patients with advanced
pulmonary fibrosis and five individuals with no pulmonary fibrosis
were examined by immunohistochemistry. Strong immunostain-
ing was evident in control lungs, with prominent PPAR-c
expression seen in interstitial fibroblasts, alveolar lining cells and
macrophages, and displaying a predominantly nuclear distribution
(Fig. 1C). In striking contrast, we found that PPAR-c was virtually
undetectable at fibrotic loci in lung biopsies from all five patients
with SSc. Immunostaining was specific for PPAR-c, as substitution
of the primary antibody with non-specific mouse IgG resulted in
complete absence of staining (not shown).
Reduced PPAR-c in explanted SSc fibroblasts
To further characterize PPAR-c expression in SSc, we
examined explanted lesional skin fibroblasts. The clinical charac-
teristics of the patients studied are shown in Table 1. Total RNA
was isolated from confluent low-passage SSc and healthy control
skin fibroblasts and examined in parallel by real-time qPCR. The
results showed substantially diminished levels of PPAR-c mRNA
in lesional fibroblasts from six SSc patients (Fig. 2A). The mean
reduction in PPAR-c mRNA levels was .70% (p=0.0006)
compared to healthy controls. These results were reproducible and
consistent over serial passage of the fibroblasts. To compare the
cellular abundance of PPAR-c protein, nuclear fractions were
subjected to Western analysis. All three SSc fibroblast lines showed
dramatically reduced levels of nuclear PPAR-c compared to
healthy control fibroblasts (Fig. 2B). Taken together, these results
demonstrate deficient PPAR-c mRNA and protein expression in
skin and lung biopsies and in explanted dermal fibroblasts from
patients with dcSSc.
TGF-ß suppresses PPAR-c expression in normal
fibroblasts
In light of the central role that TGF-ß plays in mediating the
pathogenesis of fibrosis, we sought to examine the possibility that it
might modulate the expression of PPAR-c, and that activated
TGF-ß signaling could account for impaired PPAR-c expression
seen in SSc. Previous studies have described the effects of TGF-ß
on gene expression in normal dermal fibroblasts using DNA
microarray analysis [29]. Analysis of the data showed that TGF-ß
Suppression of PPAR-c by TGF-ß
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associated with a time-dependent decrease in PPAR-c mRNA
expression (data not shown) that was accompanied by a similar
inhibition of MMP-1 and Smad3, as we had described previously
[3,6]. This decrease was mirrored by an increase in the expression
of fibrosis-related genes such as ASMA, SERPINE1, CTGF and
COMP1. In separate experiments, normal lung fibroblasts
incubated with TGF-ß showed an identical decrease in PPAR-c
mRNA expression (data not shown).
To further explore the regulation of PPAR-c mRNA expression,
confluent normal dermal fibroblasts were incubated with 10 ng/
ml TGF-ß for various periods. Under the experimental conditions
employed, there was no detectable cell toxicity due to TGF-b (data
not shown). The results of real-time qPCR demonstrated a
progressive time- and dose-dependent decrease in the levels of
PPAR-c1 and PPAR-c2 mRNA, with a maximal .70% inhibition
after 24 h (Fig. 3A and data not shown). Essentially identical
results were obtained when normal lung fibroblasts were incubated
with TGF-ß (data not shown). Suppression of PPAR-c mRNA in
TGF-ß-treated fibroblasts was further confirmed by Northern
analysis (Fig. 3B). Remarkably, we noted that the negative
regulation of PPAR-c by TGF-ß was cell type-specific. For
instance, in sharp contrast to fibroblasts, incubation of monocyte-
derived macrophages with TGF-ß caused stimulation of both
PPAR-c1 and PPAR-c2 mRNA (Fig. 3C and data not shown).
Furthermore, we found that the Th2 cytokine IL-4 stimulated
PPAR-c mRNA in macrophages, whereas it had no effect in
fibroblasts.
To evaluate the functional consequences of inhibition by TGF-
ß, we examined the regulation PPAR-c transcriptional activity.
Fibroblasts were transfected with PPRE-luc and, 18 h later,
rosiglitazone and TGF-ß were added to the cultures. Following a
further 48 h incubation, cultures were harvested and whole cell
lysates were assayed for their luciferase activities. The results
Figure 1. PPAR-c expression is reduced in SSc. A. Expression of PPAR-c and PAI-1 mRNA was determined by analyzing a previously described
skin biopsy microarray dataset from a well-characterized cohort of scleroderma patients (n=17) [25]. The fold change of mRNA levels was normalized
with the average expression level of the samples of whole cohort. Each point represents the relative PPAR-c and PAI-1 mRNA levels in dcSSc forearm
biopsies. B. Skin biopsies from patients with dSSc (n=3) and normal controls (n=3) were immunostained with antibodies to PPAR-c. C. Lung
biopsies from patients with SSc-associated advanced pulmonary fibrosis (n=5) and non-fibrotic controls (n=5) were immunostained with antibodies
to PPAR-c. Left panels, representative images. Sections incubated with preimmune serum showed absence of staining. Right panel, expression of
PPAR-c in the biopsies was scored from 0 (no immunostaining) -5 (strong immunostaining). The results shown as symbols represent the means from
five separate fields per section for each sample at magnification of 630x, and the horizontal lines represent the means.
doi:10.1371/journal.pone.0013778.g001
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activity of the PPRE promoter, TGF-ß significantly attenuated
PPRE-driven luc activity both in the presence and absence of
rosiglitazone (Fig. 4A). As expected, the cellular levels of PPAR-c
showed a marked reduction at 48 h in TGF-ß-treated fibroblasts
(Fig. 4B). These results indicate that inhibition of PPAR-c gene
expression by TGF-ß was accompanied by reduced transcriptional
activity both in the absence and presence of PPAR-c ligand.
Suppression of PPAR-c involves TbRI and the canonical
Smad signaling pathway
A series of experiments were performed in order to characterize
the cellular mechanisms underlying the potent inhibitory effect of
TGF-ß on PPAR-c expression. First, we used selective protein
kinase inhibitors to identify intracellular signaling pathways
potentially mediating the TGF-ß effect. These studies showed
that neither U0126, SB203580 nor SP600125, specific inhibitors
of the MEK1/2, p38 mitogen-activated protein kinase and c-jun
N-terminal kinase, respectively, abrogated the TGF-ß-induced
suppression of PPAR-c1 and PPAR-c2 mRNA (Fig. 5A and data
not shown). In contrast, the ALK5 inhibitor SB431542, which
blocks TßRI-mediated Smad2/3 phosphorylation, almost com-
pletely prevented the inhibitory effects. Interestingly, ALK5
blockade by itself caused a .2-fold increase in PPAR-c mRNA
levels, indicating that constitutive TGF-ß signaling causes basal
repression of PPAR-c mRNA in normal fibroblasts. Furthermore,
while TGF-ß caused a dose-dependent inhibition of PPAR-c-luc
activity in transiently transfected normal dermal fibroblasts,
pretreatment of the cultures with SB431542 completely abrogated
this effect (data not shown). These results suggest that TGF-ß-
induced inhibition of PPAR-c occurred at the level of transcription
and was mediated via the canonical Smad pathway.
Additional studies were pursued to further explore the role of the
Smad signaling in PPAR-c regulation. First, constitutively active
(TßRI
ca) or non-functional (TßRI
L45) mutants of TßRI were
ectopically expressed in normal fibroblasts. As shown in Fig. 5B,
Ad-TßRI
ca induced a dose-dependent suppression of PPAR-c1
mRNA in the absence of exogenous TGF-ß, whereas the non-
functional TßRI
L45 had no effect. Moreover, adenoviral expression
of Smad7, an inhibitory SMAD that forms stable association with
the TGF-ß receptor complex and prevents phosphorylation of
pathway-restricted Smads, blocked the inhibition of PPAR-c
mRNA by TGF-ß (Fig. 5C). As would be expected, Smad7 blocked
TGF-ß stimulation of collagen synthesis in infected fibroblasts
(Fig. 5C, right panel). Because Smad7 can abrogate both Smad2-
and Smad3-dependent responses, we sought to clarify the specific
role of cellular Smad3 in PPAR-c suppression using mouse
fibroblasts deficient in Smad3 [30]. The results showed that in
contrast to wildtype fibroblasts treated with TGF-ß, in Smad3
2/2
fibroblastsTGF-ßfailedtodown-regulatePPAR-cmRNA(Fig.5D).
As expected, TGF-ß stimulation of Type I collagen gene expression
was also lost in Smad3-deficient cells. On the other hand, transient
overexpression of Smad3 in normal human dermal fibroblasts was
by itself sufficient to repress the activity of the PPAR-c promoter
(Fig. 5E). Taken together, these results firmly establish the critical
roles of the canonical Smad signaling pathway involving TßRI and
Smad3 as both necessary and sufficient for driving transcriptional
suppression of PPAR-c in response to TGF-ß.
TGF-ß blocks PPAR-c–dependent adipogenic
differentiation
One of the key physiologic functions of PPAR-c is the
regulation of adipogenesis. Ectopic PPAR-c is both necessary
and sufficient to induce PPAR-c-dependent adipogenic differen-
Figure 2. PPAR-c expression is reduced in explanted SSc skin
fibroblasts. Dermal fibroblasts explanted from patients with dcSSc
(n=6) or healthy controls (n=4) were harvested at confluence. A. RNA
was subjected to real-time qPCR. The results shown as symbols
represent the means of triplicate determinations normalized with ß-
actin, and the horizontal lines represent the means. B. Nuclear and
cytosolic fractions were subjected to Western analysis. Representative
immunoblots.
doi:10.1371/journal.pone.0013778.g002
Table 1. Characteristic of patients with SSc.
Subject
Age
(years) Sex
Disease
duration*
(years) Sample SSc subsetN
SSc25 29 F 2 Lung dcSSc
SSc26 54 F 11 Lung dcSSc
SSc29 64 F 20 Lung dcSSc
SSc30 63 M 13 Lung dcSSc
SSc31 43 F ,1 Lung dcSSc
S20 61 M 1 Skin dcSSc
S26 52 F 2 Skin dcSSc
S30 47 F 4 Skin dcSSc
S32 40 F 5 Skin dcSSc
S35 58 F 3 Skin dcSSc
SK 45 M 2 Skin dcSSc
*From first non-Raynaud syndrome.
N dcSSc, diffuse cutaneous SSc.
doi:10.1371/journal.pone.0013778.t001
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indicated period (left panel), or for 24 h with indicated concentrations of TGF-ß (right panel). RNA expression was examined by real-time qPCR. The
results, normalized with ß-actin mRNA, represent the means 6 SD of triplicate determinations. *p,0.05. B. Total RNA was isolated following 24 h
incubation with TGF-ß, and subjected to Northern analysis. C. Fibroblasts and monocyte-derived macrophages were incubated with TGF-ß or IL-4
(both at 10 ng/ml) in parallel for 24 h, and RNA was examined by real-time qPCR. Results represent the means 6 SD of triplicate determinations.
*p ,0.05.
doi:10.1371/journal.pone.0013778.g003
Figure 4. TGF-ß suppresses PPAR-c expression in fibroblasts. A. Confluent normal dermal fibroblasts were transiently transfected with PPRE-
luc for 18 h. Cultures were preincubated with rosiglitazone (10 mM) for 60 min, followed by TGF-ß for a further 48 h. Whole cell lysates were assayed
for their luciferase activities. The results, normalized with Renilla luciferase activity, represent the means 6 SD of triplicate determinations. * p,0.05.
B. Following incubation with TGF-ß for 48 h, fibroblasts were immunostained using specific antibodies against PPAR-c (green); DAPI blue. Images
were taken under Zeiss UV Meta 510 confocal microscope (original magnification 6400).
doi:10.1371/journal.pone.0013778.g004
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effect of TGF-ß on the expression and activity of PPAR-c
prompted us to examine the modulation of adipogenesis by TGF-
ß. For this purpose, human subcutaneous preadipocytes and
normal adult dermal fibroblasts were incubated in adipogenic
differentiation media. After three cycles of adipogenic induction,
prominent intracellular lipid accumulation was evident in both
preadipocytes as well as in dermal fibroblasts (Fig. 6). That these
cells underwent adipogenic differentiation was further confirmed
by the marked up-regulation of the adipocyte-specific marker
FABP4. Inclusion of TGF-ß in the differentiation media resulted
in a substantial decrease in PPAR-c mRNA. Importantly, TGF-ß
completely prevented adipogenic differentiation in both subcuta-
neous preadipocytes and dermal fibroblasts.
The effect of rosiglitazone in TGF-ß –treated fibroblasts
By causing a substantial reduction in cellular PPAR-c
abundance, TGF-ß might be expected to attenuate the cell’s
Figure 5. Suppression of PPAR-c via TßRI and Smad3. A. Confluent foreskin fibroblasts were pre-treated with indicated protein kinase
inhibitors for 60 min, followed by incubation with 10 ng/ml TGF-ß. Cultures were harvested 24 h later and mRNA levels were analyzed by real-time
qPCR. The results, normalized with ß-actin, represent the means 6 SD of triplicate determinations. * p,0.05. B. Fibroblasts were infected with Ad-null
or Ad-TßRI
L45 (100 MOI) or indicated concentrations of Ad-TßRI
ca for 48 h, or C. Ad-Smad7 for 24 h (C). RNA subjected to real-time qPCR. The results,
normalized with ß-actin, represent the means 6 SD of triplicate determinations. * p,0.05. In C, whole cell lysates were subjected to Western analysis.
D. Confluent cultures of Smad3
2/2 or Smad3
+/+ mouse fibroblasts were incubated with 10 ng/ml TGF-ß for 24 h. RNA was subjected to real-time
qPCR. The results, normalized with 18S rRNA, represent the means 6 SD of triplicate determinations. * p,0.05. E. Normal dermal fibroblasts were
transiently transfected with PPAR-c-luc along with Smad3 expression vectors. Following a 24 h incubation, cultures were harvested and whole cell
lysates were assayed for their luciferase activities. The results, normalized with Renilla luciferase activity, represent the means 6 SD of triplicate
determinations. ** p,0.005. In A, C, D, open bars, untreated cultures; closed bars, TGF-ß-treated cultures.
doi:10.1371/journal.pone.0013778.g005
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the regulation of FABP4, a cardinal endogenous target for
activated PPAR-c was studied. Confluent dermal fibroblasts were
incubated with TGF-ß, with rosiglitazone added to the cultures
after 24 h. Following a further 24 h incubation, cultures were
harvested. As shown in Fig. 7A, in the presence of TGF-ß,
rosiglitazone failed to induce full stimulation of FABP4. These
results indicate that TGF-ß exposure resulted in partial loss of
PPAR-c–dependent adipogenic effects of rosiglitazone, presum-
ably due to the marked decrease in cellular PPAR-c abundance
induced by exposure to TGF-ß. In contrast, rosiglitazone was
capable of partially reducing the stimulation of collagen and
ASMA expression when given 24 h following TGF-ß treatment
(Fig. 7A–C). These results indicate that TGF-ß markedly
attenuated the adipogenic activities of the synthetic PPAR-c
ligand, while only partially attenuating its anti-fibrotic activities,
suggesting that the latter might also involve some PPAR-c-
independent mechanisms.
Reduced expression of PPAR-c target genes in SSc skin
In a previous report using microarray-based genome-wide
expression profiling of scleroderma skin biopsies, a pattern of gene
expression consistent with active TGF-ß signaling was observed in
subsetsofSScpatientswith diffusecutaneousdisease[29].Inlightof
the potent inhibitory effects of TGF-ß on PPAR-c demonstrated in
our studies, we sought to evaluate the expression of PPAR-c-
regulated genes in the subset of dcSSc patients whose skin biopsies
showed a prominent ‘‘TGF-ß activated signature’’. A list of 87
putative PPAR-c target genes was compiled from an extensive
literature review. The expression of these genes was then examined
in a gene expression microarray dataset from a well-characterized
cohort of SSc patients [25]. None of these patients were receiving
thiazolidinediones at the time of the biopsies. The data, organized
by hierarchical clustering based on the expression level of TGF-ß-
responsive genes as demonstrated previously [29], are shown as
TGF-ß-activated (red) and TGF-ß-not activated (black) clusters.
PPAR-c target genes compiled from literature review showed
decreased expression in biopsies from the TGF-ß-activated dcSSc
subset compared to the TGF-ß-not activated SSc subset, or to
healthy controls (Fig. 8). The significance of differential regulation
for each gene was determined using Significance Analysis of
Microarrays (SAM). There were forty-one putative PPAR-c target
genes with significant differential expression in the TGF-ß-activated
versus TGF-ß-not activated SSc subsets (FDR ,0.78%). Thirty-
three of these PPAR-c target genes (80%) showed reduced
expression in the TGF-ß-activated group, and elevated expression
in the TGF-ß-not-activated group (Fig. 8).
Discussion
Excessive extracellular matrix accumulation and tissue contrac-
tion, the hallmarks of fibrosis, are mediated by fibroblasts and
myofibroblasts activated by TGF-ß [1]. Blocking TGF-ß activity
therefore represents an appealing approach to fibrosis therapy, and
there is intense interest in identifying the intracellular pathways that
positively or negatively modulate the fibrotic responses. Recent
research findings suggest that PPAR-c signaling is a novel cell-
intrinsic mechanism to negatively regulate profibrotic responses.
PPAR-c exerts potent antifibrotic effects in vitro and in vivo.
We showed previously that PPAR-c activation by natural or
synthetic ligands abrogated collagen synthesis, cell migration and
myofibroblast transdifferentiation induced by TGF-ß [21]. While
the precise mechanisms underlying abrogation of TGF-ß signaling
remain to be fully delineated, we found that PPAR-c blocked
Smad-dependent transcriptional responses without interfering
with Smad phosphorylation or nuclear accumulation. Instead,
PPAR-c appears to compete with ligand-inducible transcription
Figure 6. TGF-ß inhibits adipogenic differentiation of mesenchymal cell. Confluent human subcutaneous preadipocytes or adult dermal
fibroblasts were induced to undergo adipogenic differentiation in vitro. Subcutaneous preadipocytes were incubated with maintenance media, or
differentiation media alone or in the presence of TGF-ß (upper panels). Dermal fibroblasts were incubated with DMEM, or DM-2/AM-1 for three cycles
followed by incubation with 10 ng/ml TGF-ß for a further 3 weeks (lower panels), and photographed under a phase contrast microscope. Arrows
indicate intracellular accumulation of oil droplets. Original magnification X200.
doi:10.1371/journal.pone.0013778.g006
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complex formation in TGF-ß-stimulated fibroblasts [14]. Further-
more, in animal models of TGF-ß-dependent fibrosis, rosiglitazone
treatment attenuated the development of dermal thickness and
collagen accumulation in vivo [21,32]. Because the biological
activities of PPAR-c ligands depend largely on their interaction with
PPAR-c, the relative levelsorbiologicallyavailabilityofPPAR-care
important factors governing the intensity of ligand-induced cellular
responses. Surprisingly, little is known about the expression of
PPAR-c in fibroblasts, and its regulation during inflammation,
tissue repair and fibrosis. In the present studies we found that the
levels of PPAR-c protein and mRNA were substantially lower in
SSc lesional tissue and explanted skin fibroblasts than in healthy
controls. Moreover, genome-wide expression analysis using micro-
arrays demonstrated that SSc skin biopsies with evidence of active
TGF-ß signaling had low expression of PPAR-c-regulated genes,
revealing an inverse relationship between TGF-ß activity and
PPAR-c-dependent responses in fibrotic tissues.
We examined the regulation of PPAR-c by TGF-ß in normal
fibroblasts. Despite its importance in determining the intensity of
ligand-induced responses, the factors involved in the regulation of
PPAR-c expression are not well understood. Our results
demonstrated that TGF-ß caused a potent time- and dose-
dependent and cell-type specific down-regulation of PPAR-c
transcription. This inhibitory response was mediated through the
canonical Smad signal transduction pathway. A 2.7 kb fragment
of the PPAR-c gene promoter harboring two putative Smad
binding elements was sufficient for inhibition by TGF-ß. Taken
together with previous findings, the present results indicate that
TGF-ß and PPAR-c are engaged in a mutually antagonistic
reciprocal cross-talk, whereby the PPAR-c pathway abrogates
cellular responses induced by TGF-ß, while TGF-ß-Smad inhibits
the expression of PPAR-c and its target genes.
In addition to TGF-ß, IL-13, Wnt, CCN2, as well as hypoxia,
have all been shown to inhibit PPAR-c expression or activity
[33,34,35,36,37]. Particularly interesting is lysophosphatidic acid
(LPA), a bioactive lipid that potently inhibits the expression of
PPAR-c in a variety of cell types [38], while also acting as a
PPAR-c agonist [39]. The signaling mechanisms mediating down-
regulation of PPAR-c in response to these cues are not well
understood. It is noteworthy that CCN2 and Wnt are known to be
up-regulated in the fibrotic cellular milieu in SSc, and chronic
tissue hypoxia due to microvascular insufficiency is prominent
[1,40]. Thus, multiple factors implicated in the pathogenesis of
fibrosis might contribute to the profound down-regulation of
PPAR-c in SSc. We and others have also observed that PPAR-c
protein and mRNA levels were persistently reduced in explanted
SSc fibroblasts [17]. At present, it is unclear whether autonomous
Figures 7. Rosiglitazione abrogates TGF-ß–induced fibroblast activation. Confluent dermal fibroblasts were pretreated with TGF-ß for 24 h,
followed by rosiglitazone (10 mM) for further 24 h. A. Total RNA was analyzed by real-time qPCR. The results, normalized with 18S, represent the
means 6 SD of triplicate determinations. * p,0.05. B. Whole cell lysates were subjected to Western analysis. C. Fibroblasts were fixed and stained
with antibodies to a-smooth muscle actin (green color). Nuclei were visualized by DAPI (blue). Original magnification X 200.
doi:10.1371/journal.pone.0013778.g007
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gene regulation, such as epigenetic modifications at the PPAR-c
promoter, or results from constitutive autocrine TGF-ß stimula-
tion. The latter mechanism is plausible in light of the finding that
in normal fibroblasts, constitutive basal TGF-ß signaling maintains
tonic suppression of PPAR-c (Fig. 5A). Epigenetic modification
represents an appealing possibility to account for low level of
PPAR-c gene expression, since methylation-mediated silencing of
inhibitory transcription factors such as Fli1 or Smad7 has been
implicated as a mechanism for autonomous activation of SSc
fibroblasts [41,42]. While we cannot fully exclude the possibility
that hypermethylation of the regulatory elements of the PPAR-c
gene result in gene silencing in SSc fibroblasts, in preliminary
studies the methylation inhibitor 5-azacytidine failed to normalize
PPAR-c expression (data not shown).
Analysis of microarray data from SSc skin biopsies previously
identified a patient subset with a ‘‘TGF-ß-responsive gene
signature’’ [25]. This pattern of gene expression was only seen
in biopsies from patients with dcSSc, and was not found in biopsies
from patients with other forms of scleroderma, or from healthy
controls. The ‘‘TGF-ß responsive signature’’ identifies a subset of
scleroderma patients with extensive skin involvement and
propensity to pulmonary fibrosis [29]. Remarkably we observed
that the expression of a majority of differentially regulated PPAR-c
target genes (80%) was diminished in the ‘‘TGF-ß responsive gene
signature’’ subset biopsies. These observations reveal an inverse
relationship in the tissue expression of TGF-ß-inducible genes and
PPAR-c inducible genes, a result not unexpected in view of our
present findings that TGF-ß suppresses PPAR-c expression and
transcriptional activity in fibroblasts, and our previous demon-
stration that PPAR-c directly inhibits Smad-mediated TGF-ß
responses. The reciprocal relationship between the expressions of
these two sets of genes is consistent with a mutually antagonistic
cross-talk of the TGF-ß and PPAR-c pathways. In this context it is
remarkable that diminished PPAP-c expression or function is a
recurring theme in human fibrotic conditions and animal models
of fibrosis. For example, intracellular PPAR-c levels were
diminished in alveolar macrophages from patients with pulmonary
fibrosis [43], and in the fibrotic lesions in cicatrical alopecia [24].
In addition to the association of low PPAR-c with fibrosis in
various human disorders, evidence for a causal relationship comes
from animal models. Tissue-specific down-regulation of PPAR-c,
whether due to loss-of-function mutations [44], genetic targeting
[45,46], or overexpression of PPAR-c inhibitors such as TGF-ß or
Wnt [47,48], is invariably accompanied by exuberant local
fibrosis. It is intriguing that in SSc, skin fibrosis is commonly
Figure 8. Reduced PPAR-c target gene expression in SSc skin. Gene expression in lesional skin biopsies was examined by analysis of a
previously described microarray dataset based on biopsies from patients with SSc (n=17, red) and healthy controls (n=6, green) [29]. Samples were
ordered based on their TGF-ß-activated signature (red branches, TGF-ß-activated signature; black branches, TGF-ß not activated). Of forty-one PPAR-c
target genes showing significant differential expression in SSc, thirty-three are down-regulated in samples with TGF-ß-activated gene signature,
whereas eight genes show the inverse expression pattern.
doi:10.1371/journal.pone.0013778.g008
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some biopsies, complete adipose tissue atrophy [49]. We speculate
that in these cases active TGF-ß signaling in the dermis suppresses
PPAR-c in situ with consequent disruption of adipogenesis, loss of
adipocytes and lipoatrophy. These observations highlight the
importance of a functional antagonism between profibrotic TGF-ß
signaling on the one hand, and the anti-fibrotic PPAR-c pathway
on the other, in the pathogenesis of SSc.
One of the critical mechanisms employed by TGF-b in the
promotion of fibrosis is epithelial-mesenchymal transition (EMT)
[50]. In this study, we observed reduced levels of epidermal PPAR-
c in SSc skin biopsies, whereas normal skin biopsies showed strong
immunostaining in the basal epidermis (Figs 1B). High level of
TGF-ß and ASMA expression in the basal epidermis have been
reported previously [51]. Because PPAR-c signaling potently
inhibits TGF-b-induced EMT in vitro [52], these observations
raise the possibility that an important physiologic role of PPAR-c
in the epidermis is to prevent deregulated EMT, and its loss in SSc
may contribute to promotion of EMT and fibrosis.
Since a primary biological function of PPAR-c is to serve as an
intracellular sensor for changes in fatty acid or prostaglandin
levels, its abundance and availability are important in determining
the intensity of ligand responses. Cellular responses elicited by
endogenous ligands, such as adipogenic differentiation of mesen-
chymal progenitor cells, are dependent on PPAR-c signaling [31].
We have previously shown that augmenting levels of PPAR-c by
means of ectopic overexpression enhanced the cellular respon-
siveness to a PPAR-c ligand [13,53]. In light of the potent down-
regulation of PPAR-c observed in TGF-ß-treated cells, we
anticipated that TGF-ß might reduce cellular sensitivity to
PPAR-c ligands. We found however that fibroblast activation
was blunted by rosiglitazone even when it was added to the
cultures 24 h after TGF-ß. Therefore, synthetic PPAR-c ligands
are capable of abrogating profibrotic responses even in the face of
low PPAR-c abundance. Currently approved PPAR-c ligands
such as rosiglitazone have been linked to side effects, including
fluid retention, heart failure, and other cardiovascular events,
raising questions regarding their safety [54]. Novel PPAR-c
agonists with selective activity and potentially improved safety are
under active investigation [55].
In summary, these results reveal that PPAR-c expression and
activity are impaired in SSc, which is correlated with active TGF-ß
signaling and fibrosis in lesional tissues. There exists a reciprocal
relation between the expression of TGF-ß-activated genes and
PPAR-c-regulated genes in lesional tissue and in explanted SSc
fibroblasts. PPAR-c plays a physiologic role in tissue remodeling as
a negative regulator of fibroblast activation and differentiation,
which is highlighted by the link between loss of PPAR-c and
spontaneous emergence of fibrosis. Reduced PPAR-c in SSc,
resulting from its suppression by TGF-ß and related cytokines,
hypoxia and other mechanisms might contribute to unchecked
fibroblast activation and persistent fibrogenesis.
Materials and Methods
Ethics statement
The protocols for human tissue collection were approved by the
Institutional Review Boards for Human Studies at Northwestern
University and University of Pittsburgh. A written informed
consent was obtained from all participants.
Cell cultures
Primary cultures of dermal fibroblasts were established by
explantation from biopsies of neonatal foreskins, or from affected
dorsal forearm of seven patients with SSc and four healthy controls
[3,56]. Only patients with diffuse cutaneous SSc (dcSSc) who were
not receiving treatment with corticosteroids were studied. Primary
cell cultures were also established from the dorsal skin of newborn
Smad3-null (Smad3
–/–) mice or wildtype (Smad3
+/+) littermates
[30]. Unless otherwise indicated, all fibroblasts were maintained at
37uC in an atmosphere of 5% CO2 in Eagle’s Minimum Essential
Medium (EMEM) or Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS), 1%
vitamins, 1% penicillin/streptomycin, and 2 mM L-glutamine (all
from BioWhittaker, Walkersville, MD), and studied between
passages 4 and 8. When fibroblasts reached early confluence, fresh
media containing TGF-ß (Genzyme, Framingham, MA) were
added to the cultures. In selected experiments, cultures were
pretreated with 15d-PGJ2 (BioMol, Plymouth Meeting, PA),
troglitazone (GlaxoSmithKline, King of Prussia, PA), rosiglitazone
(Cayman Chemical, Ann Arbor, MI), interleukin-4 (IL-4) or
platelet-derived growth factor (PDGF) (both from Sigma, St. Louis,
MO) for indicated periods. In other experiments, the protein kinase
inhibitors U0126 (Cell Signaling Technology, Beverly, MA),
SB431542 or SB203580 (both from Sigma) at 10 mM, or
SP600125 (Sigma) at 20 mM, were added to the cultures 60 min
prior to TGF-ß. In experiments focusing on profibrotic responses in
fibroblasts, TGF-b at 10 ng/ml, a concentration shown to be
maximally effective and non-toxic in prior studies, was used. Cell
viability was determined by Trypan blue dye exclusion.
Human peripheral blood macrophages were isolated from buffy
coats from healthy donors (Lifesource, Glenview, IL) by
Histopaque (Sigma) gradient centrifugation followed by counter-
current centrifugal elutriation (JE-6B, Beckman Coulter, Palo
Alto, CA). Isolated monocytes were $90% pure as determined by
morphology, non-specific esterase staining and CD14 expression
by flow cytometry. Following adherence to plates for 60 min,
monocytes differentiated into macrophages for seven days in
Roswell Park Memorial Institute (RPMI) media containing 20%
heat-inactivated FBS, L-glutamine, and penicillin and streptomy-
cin, and used in experiments.
Adipogenic differentiation
Human subcutaneous preadipocytes (Zen-Bio Inc, Research
Triangle Park, NC) or low-passage adult dermal fibroblasts were
induced to undergo in vitro adipogenic differentiation as
previously described [57]. Briefly, when cells reached confluence,
cultures were incubated in DM-2 adipogenic induction media for
three days, followed by AM-1 adipogenic maintenance media for a
further three days (both from Zen-Bio). This cycle was then
repeated three times. Following the final DM-AM cycle,
incubation in AM was continued for up to a further 28 days
prior to harvesting.
Northern analysis and real-time quantitative PCR
Total RNA was isolated from confluent fibroblasts using TRIzol
Reagent (Invitrogen, Carlsbad, CA), and levels of mRNA were
determined by Northern analysis or real-time quantitative PCR
(qPCR). Northern analysis was performed using a-
32P-labeled
human PPAR-c 1 cDNA probes [13]. Following washing of the
nitrocellulose membranes, the RNA-cDNA hybrids were visual-
ized by autoradiography. For real-time quantitative qPCR, reverse
transcription were performed using SuperScript First-strand
synthesis system (Invitrogen) according to the manufacturer’s
protocol. For real-time qPCR, reactions were performed on ABI-
Prism 7300 sequence detection PCR machine (Applied Biosystem,
Forster City, CA) according to the manufacturer’s protocol [58].
The primers used for qPCR are listed in Table 2. Relative mRNA
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RNA levels and determined by calculating DDCt.
Plasmids and adenoviruses
The PPAR-c–luc plasmid contains 2.7 kb of the 59 flanking
region of the human PPAR-c gene promoter linked to the luciferase
reporter gene [59,60]. The PPRE-luc plasmid contains 3 tandem
copies of the PPAR response element (PPRE) sequence of the acyl-
coenzyme A oxidase gene linked to thymidine kinase and luciferase
genes [61]. A Smad3 expression vector has been previously
described [62]. Replication-incompetent adenoviral vectors ex-
pressing constitutively active human TßRI (Ad-TßRI
ca), L45 loop-
mutated TßRI that lacks Smad binding ability (Ad-TßRI
L45), and
control adenovirus (Ad-null) were from Vesa Kaartinen [63].
Transient transfection assays and adenovirus infections
Fibroblasts (10
5 cells/well) were seeded in 12-well plates, and at
early confluence, transiently cotransfected with reporter constructs
and expression vectors or appropriate empty vectors using
Superfect Reagent (Qiagen, Valencia, CA), or infected with
adenoviruses. Following incubation with TGF-ß for 24 h, cultures
were harvested and whole cell lysates were assayed for their
luciferase activities [13]. The pRL-TK Renilla luciferase (pRL-
TK-Luc) plasmid was used in each transfection experiment as an
internal control. Experiments were performed in triplicate.
Western analysis
At the end of the incubation periods, cultures were harvested,
whole cell lysates or nuclear or cytosolic fractions were prepared,
and aliquots containing equal amounts of proteins (10–15 mg) were
subjected to Western analysis [13]. Membranes were immuno-
bloted with primary antibodies to human PPAR-c (1:250 dilution)
[64], Smad1/2/3, actin, TßRI, Smad7 (1:200 dilution, all from
Santa Cruz Biotechnology, Santa Cruz, CA), Smad3 (1:250
dilution; Zymed), phospho-Smad2 (1:1000 dilution; Cell Signaling
Technology, Danvers, MA) or Type I collagen (1:400 dilution;
Southern Biotechnology, Birmingham, AL). Membranes were
then washed and incubated with appropriate secondary antibodies
for 45 min, and antigen–antibody complexes were visualized by
chemiluminescence (Pierce Biotechnology, Rockford, IL) accord-
ing to the manufacturer’s instructions. The results were normal-
ized against the intensity of the ß-actin in each sample.
Immunocytochemistry
Fibroblasts were seeded on cover slides in a 6-well chamber and
incubated in serum-free EMEM containing 0.1% BSA, TGF-ß
(10 ng/ml) and rosiglitazone (10 mM). At the end of the incubation
periods, cells were fixed and processed for immunocytochemistry
[65]. The slides were incubated with primary antibodies against
PPAR-c or a-smooth muscle actin for 120 min, followed by
AlexaH 488-conjugated chicken-anti-rabbit IgG or chicken-anti-
mouse IgG (Invitrogen) for 60 min. Nuclei were identified with 49-
6-Diamidino-2-phenylindole (DAPI). Non-immunized IgG was
used in each experiment as a negative control. Following stringent
washing, slides were examined using Zeiss UV Meta 510 confocal
microscope (Carl Zeiss, Jena, Germany). Each experiment was
repeated at least three times with consistent results.
Immunohistochemistry
Lung tissues were obtained from five patients with SSc-
associated pulmonary fibrosis who were undergoing lung trans-
plant surgery and from unused normal lungs from five donors.
Sections (5 mm) were deparaffinized, rehydrated and immersed in
TBS-T buffer (Tris-buffered saline 20.1%Tween 20), treated with
target retrieval solution (DAKO, Carpinteria, CA) at 95uC for
10 min and incubated with primary antibody against PPAR-c
(1:100 dilution, Santa Cruz). Bound antibodies were detected
using secondary antibodies and System-HRP (DAB) (Dako,
Glostrup, Denmark). Substitution of the primary antibody with
isotype-matched irrelevant IgG served as negative controls.
Sections were counterstained with hematoxylin, mounted with
Permount (Fisher Scientific, Pittsburgh, PA) and viewed under an
Axioskop microscope (Carl Zeiss). Pictures were taken and
modified by Nuance Multiple Spectra CCD with Nuance 2.10
software. To quantify PPAR-c expression, cells in five microscopic
fields in each sample were scored as clearly immunopositive or
negative for PPAR-c by two independent examiners, and the ratio
of positive cells to total cells in each field was calculated.
DNA microarray analysis
The generation and analysis of the microarray dataset using skin
biopsies from patients with SSc and normal controls was described
previously [25]. The results of microarray analysis were ordered
according to their ‘‘TGF-ß-responsive gene signature’’ expression
[29]. To interrogate the expression of PPAR-c target genes in the
dataset, 87 genes known from the literature to be regulated by
PPAR-c were extracted from the microarray data. Those genes
showing statistically significant differences in expression between
‘‘TGF-ß activated’’ and ‘‘TGF-ß not activated’’ subsets were
selected for examination.
Statistical analysis
The data are presented as means 6 SD of multiple
determinations. The significance of differences between experi-
mental and control groups was determined by Student’s t-test
using GraphPad t-test calculator. A value of p,0.05 was
considered statistically significant. For analysis of microarray data,
Significance Analysis of Microarrays (SAM) using the Student’s t-
test function and data randomization to establish a False Discovery
Rate (FDR) was used. Forty-one genes were selected with an FDR
(q-value) of #0.78%.
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